ArticleOpinion/VideoPHN-05842026-11-02 11:23 CT

Opinion: FDA peptide policy risks undermining drug development and patient safety

Source · BioSpace

TLDR

In a BioSpace opinion article, pharmacist Robert Popovian criticizes an HHS interim policy allowing compounding of six unapproved peptides while FDA considers its final position. He argues that broader commercial access without adequate clinical evidence could threaten patient safety and weaken incentives for drug development.

01—Key points

01The article says FDA scientific reviewers opposed all seven peptides considered, while an advisory committee recommended six.
02Reviewers reportedly found insufficient effectiveness evidence for BPC-157 in ulcerative colitis and no human clinical data supporting KPV’s proposed uses.
03HHS cites additional testing and exposure information; Popovian argues quality controls cannot replace clinical studies.

Why it matters Editorial

The policy raises questions about access to unapproved peptides, evidence standards, and incentives to conduct clinical research.

Read the original at BioSpace↗

Summary generated with AI and reviewed by an editor. The original source governs; summaries can contain errors. Information only — not medical advice. Full disclaimer.